SunWay Biotech Co., LTD. (TPEX: 1271)
Taiwan
· Delayed Price · Currency is TWD 90.00
+0.10 (0.11%)
Sep 10, 2024, 1:14 PM CST
SunWay Biotech Co., LTD. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 810.99 | 571.11 | 425.35 | 380.43 | 314.48 | 172.19 | Upgrade
|
| Revenue Growth (YoY) | 64.69% | 34.27% | 11.81% | 20.97% | 82.64% | 58.48% | Upgrade
|
| Cost of Revenue | 387.74 | 334.2 | 275.46 | 109.32 | 106.02 | 63.51 | Upgrade
|
| Gross Profit | 423.25 | 236.91 | 149.89 | 271.11 | 208.46 | 108.68 | Upgrade
|
| Selling, General & Admin | 271.87 | 179.59 | 111.03 | 60 | 49.59 | 40.33 | Upgrade
|
| Research & Development | 34.78 | 6.21 | - | 43.38 | 32.99 | 26.26 | Upgrade
|
| Operating Expenses | 307.09 | 186.77 | 110.66 | 103.82 | 82.58 | 66.59 | Upgrade
|
| Operating Income | 116.16 | 50.14 | 39.23 | 167.29 | 125.88 | 42.09 | Upgrade
|
| Interest Expense | -4.11 | -2.09 | -1.15 | -0.09 | -0.2 | -0.64 | Upgrade
|
| Interest & Investment Income | 2.44 | 1.79 | 0.23 | 0.06 | 0.04 | 0.05 | Upgrade
|
| Earnings From Equity Investments | -0.17 | - | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 3.54 | 3.29 | 1.7 | -0.12 | -0.06 | -0.16 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.79 | 1.14 | -0.38 | 3.21 | 0.14 | 2.67 | Upgrade
|
| EBT Excluding Unusual Items | 118.66 | 54.28 | 39.63 | 170.35 | 125.81 | 44.03 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.09 | Upgrade
|
| Asset Writedown | - | - | - | -0.14 | -0.11 | -4.52 | Upgrade
|
| Pretax Income | 118.97 | 54.28 | 39.63 | 170.21 | 125.7 | 39.59 | Upgrade
|
| Income Tax Expense | 19.02 | 9.85 | 8.29 | 0.49 | - | 1.36 | Upgrade
|
| Earnings From Continuing Operations | 99.95 | 44.42 | 31.34 | 169.72 | 125.7 | 38.24 | Upgrade
|
| Minority Interest in Earnings | -0.35 | -0.35 | -1.3 | -0.96 | 0.02 | - | Upgrade
|
| Net Income | 99.6 | 44.08 | 30.04 | 168.76 | 125.71 | 38.24 | Upgrade
|
| Net Income to Common | 99.6 | 44.08 | 30.04 | 168.76 | 125.71 | 38.24 | Upgrade
|
| Net Income Growth | - | 46.71% | -82.20% | 34.24% | 228.78% | - | Upgrade
|
| Shares Outstanding (Basic) | 49 | 30 | 20 | 33 | 31 | 31 | Upgrade
|
| Shares Outstanding (Diluted) | 49 | 30 | 20 | 34 | 32 | 33 | Upgrade
|
| Shares Change (YoY) | 259.82% | 50.70% | -41.13% | 5.76% | -3.72% | 6.71% | Upgrade
|
| EPS (Basic) | 2.03 | 1.47 | 1.52 | 5.10 | 4.02 | 1.23 | Upgrade
|
| EPS (Diluted) | 2.02 | 1.47 | 1.51 | 5.00 | 3.94 | 1.15 | Upgrade
|
| EPS Growth | - | -2.65% | -69.80% | 26.90% | 242.61% | - | Upgrade
|
| Free Cash Flow | -15.93 | 9.75 | 42.58 | 151.05 | 180.3 | 74.68 | Upgrade
|
| Free Cash Flow Per Share | -0.32 | 0.33 | 2.14 | 4.47 | 5.65 | 2.25 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | 3.240 | 4.350 | 2.800 | - | Upgrade
|
| Dividend Growth | -69.14% | -69.14% | -25.52% | 55.36% | - | - | Upgrade
|
| Gross Margin | 52.19% | 41.48% | 35.24% | 71.26% | 66.29% | 63.12% | Upgrade
|
| Operating Margin | 14.32% | 8.78% | 9.22% | 43.97% | 40.03% | 24.45% | Upgrade
|
| Profit Margin | 12.28% | 7.72% | 7.06% | 44.36% | 39.98% | 22.21% | Upgrade
|
| Free Cash Flow Margin | -1.96% | 1.71% | 10.01% | 39.71% | 57.33% | 43.37% | Upgrade
|
| EBITDA | 157.76 | 64.02 | 44.22 | 177.12 | 136.89 | 54.42 | Upgrade
|
| EBITDA Margin | 19.45% | 11.21% | 10.40% | 46.56% | 43.53% | 31.60% | Upgrade
|
| D&A For EBITDA | 41.6 | 13.88 | 4.99 | 9.83 | 11.01 | 12.33 | Upgrade
|
| EBIT | 116.16 | 50.14 | 39.23 | 167.29 | 125.88 | 42.09 | Upgrade
|
| EBIT Margin | 14.32% | 8.78% | 9.22% | 43.97% | 40.03% | 24.45% | Upgrade
|
| Effective Tax Rate | 15.99% | 18.15% | 20.91% | 0.29% | - | 3.42% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.